Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT06604260 Sponsor: Dalia Lartey Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT06604260
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Group 1 – Crohn's Disease:

  • You are 18 years or older and have been diagnosed with Crohn's disease
  • AND at least one of the following applies to you:
  • You experience gut symptoms such as diarrhea, bloody or loose stools, stomach pain, or symptoms of blockage in the gut
  • Your blood or stool test results show signs of inflammation above certain levels (confirm with trial site)
  • A camera examination (endoscopy) has shown active disease in your gut
  • A scan or ultrasound has shown signs of active disease, such as thickening of the bowel wall

Group 2 – Ulcerative Colitis:

  • You are 18 years or older and have been diagnosed with ulcerative colitis
  • AND at least one of the following applies to you:
  • A camera examination (endoscopy) has shown active disease in your gut
  • An ultrasound of your gut has shown signs of active disease, such as a thickened bowel wall
  • Your blood or stool test results show signs of inflammation above certain levels (confirm with trial site)

Who may not be able to join:

  • You are currently pregnant
  • You are not able to give your own consent to take part in the trial
  • You have had surgery related to your bowel condition within the last 5 years
  • You have been diagnosed with bowel (colorectal) cancer

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Mark Lowenberg, MD PhD, Amsterdam UMC

Phone: +31205668160

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Dalia Lartey
Registry
ClinicalTrials.gov
Start date
31 August 2023
Est. completion
31 December 2024

Where this trial is recruiting

🇳🇱 Netherlands

Primary endpoints

Detection of areas with increased 68Ga-FAPi uptake in Crohn's disease patients; Detection of areas with increased 68Ga-FAPi uptake in ulcerative colitis patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov